Finoriq research workspace
XBiotech Inc. (XBIT) Company Overview
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for. Review XBIT filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
- Company
- XBiotech Inc. (XBIT)
- Ticker
- XBIT
- Market Cap
- $68.6M
- Latest Price
- $2.2501
- Industry
- Biotech & Pharma
XBiotech Inc. (XBIT) Current Valuation Metrics
Static valuation preview for XBiotech Inc. (XBIT). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -57.5% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -60.4% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.52x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.